New Zealand is the newest country to pre-order bulk doses of the COVID-19 vaccine lately in progression through the German company BioNTech (BNTX) and its spouse Pfizer (PFE).
The German biotechnology company, one of the pioneers in the race to expand a coronavirus vaccine, has signed an agreement to supply New Zealand with 1. 5 million doses of its vaccine, which is expected to be available in the first quarter of 2021. .
New Zealand imposed an early and strict closure to restrict the pandemic and has reported 1,800 cases of COVID-19 and 25 deaths to date.
One of BioNTech’s messenger RNA vaccine applicants is recently in phase 3 trials. The company announced in September that it had purchased a new production plant to increase production once its vaccine was approved.
Last week, the European Medicines Agency, the EU regulator, said it was accelerating its processes to allow immediate approval of the BioNTech vaccine once it submitted its protection verification data.
The vaccine being developed through AstraZeneca and oxford University is also being tested from this new framework faster through the EMA.
The European Commission has announced that it will buy two hundred million doses of BioNTech-Pfizer, with the option to purchase another hundred million doses.
READ ALSO: Germany backs 3 nationals with 750 million euros to expand COVID-19 vaccine
In August of this year, Pfizer and BioNTech reached an agreement to supply the US government with a nuclear power of action. But it’s not the first time One hundred million doses of its coronavirus vaccine as a component of a $1. 95 billion (1. 49 billion pound) deal as a component of the government’s Warp Speed operation: a boost to deliver three hundred million doses of COVID-19 vaccines through the end of the year.
BioNtech and Pfizer, AstraZeneca and Oxford University, Modern (MRNA), Novavax (NVAX), Johnson
READ ALSO: CureVac works for one hundred million doses of the COVID-19 vaccine until the end of 2020
BioNTech was one of 3 German corporations to obtain a combined monetary sum of 750 million euros (680 million pounds, 885 million dollars) from the Berlin government. It was also decided by CureVac and IDT Biologika. The agreement with the 3 national corporations would guarantee Germany 40 million doses of vaccine.
Curevac went on the Nasdaq in August this year and has AstraZeneca (AZN). L) its investors.
OBSERVE: Oxford vaccine trial resumes